What Researchers Did
Researchers conducted a randomized clinical trial to evaluate the effect of hyperbaric oxygen therapy on HMGB1/NF-κB expression and neurological outcomes in 79 patients with acute spinal cord injury.
What They Found
Compared to conventional treatment, hyperbaric oxygen therapy significantly down-regulated HMGB1 and NF-κB expression from day 3 to day 30 (p < 0.05). It also decreased F-wave chronodispersion at days 10 and 30 (p < 0.01), and improved ASIA and Frankel Grade motor/pain scores by day 30 (p < 0.01).
What This Means for Canadian Patients
Canadian patients with acute spinal cord injury might experience improved neurological recovery and reduced inflammatory markers if hyperbaric oxygen therapy is incorporated into their treatment. This could potentially lead to better long-term functional outcomes and quality of life.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
The study's relatively short follow-up period of 30 days may limit the assessment of long-term neurological recovery and sustained effects of hyperbaric oxygen therapy.